Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 1)
On July 9, 2018, FDA hosted a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA was interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA was particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies. For more information, visit the meeting webpage: https://go.usa.gov/xATVF
Видео Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 1) канала U.S. Food and Drug Administration
Видео Public Meeting: Patient-Focused Drug Development for Chronic Pain (Part 1) канала U.S. Food and Drug Administration
Показать
Комментарии отсутствуют
Информация о видео
22 декабря 2020 г. 0:46:25
01:58:49
Другие видео канала
The Biosimilar Development ProcessNonclinical Safety Assessment for Small Molecules and Biologic Drug Development (6of14) REdI 2018Is My Product A Medical DeviceDiversity in Clinical Trials: Learn about Enrollment Trends and Resources from FDAEliminate the Gap: Addressing Cancer Disparities in the US Latinx LGBTQ+ CommunityData Requirements for BiosimilarsFDA CDER Regulatory Science: Patient-Focused Drug DevelopmentPublic Meeting: Patient-Focused Drug Development for Systemic SclerosisPublic Meeting: Patient-Focused Drug Development for VitiligoOverview of Non-clinical Assessment in Drug Development (8/14) REdI 2017Referencing Approved Drug Products in ANDA SubmissionsEstablishment Registration and Drug Listing Compliance Program – DRLS Workshop 2020Establishment Registration– DRLS Workshop 2020FDA's Low- or No- Cost Tech Enabled Traceability ChallengeVaccines and Related Biological Products Advisory Committee - 12/10/2020FDA Drug Manufacturing Inspections - REdI 2020Stakeholder Call: Pfizer-BioNTech COVID-19 Vaccine Booster Dose - 9/24/21New Approaches for an Integrated Nonclinical-Clinical QT/Proarrhythmic Risk Assessment (1 of 2)Vaccines and Related Biological Products Advisory Committee – 2/26/20212021 FDA Science Forum - Keynote Session and Sessions 1 and 3